CareDx experienced dramatic financial volatility with revenue surging 296% while simultaneously swinging from $52.5M net income to -$21.4M loss, coupled with aggressive $87.8M share buybacks despite burning through $49M in cash.
The company appears to be in a rapid growth phase but at significant cost to profitability, suggesting either major operational challenges or strategic investments that haven't yet paid off. The massive share buyback program while burning cash and posting losses raises questions about capital allocation strategy and management's confidence in the business trajectory.
CareDx delivered exceptional revenue growth of 296% to $48.3M with gross profit nearly doubling, indicating strong market demand for their precision medicine solutions. However, the company simultaneously experienced a dramatic profitability collapse, swinging from $52.5M net income to -$21.4M loss, while cash reserves dropped 43% to $65.4M and debt increased 42%. The aggressive $87.8M share buyback program during a loss-making period, combined with significant increases in capital expenditure and inventory buildup, suggests the company is investing heavily for future growth while prioritizing shareholder returns despite current operational challenges.
Share repurchases increased 16713.8% — management returning capital, signals confidence in intrinsic value.
Capital expenditure jumped 994.1% — major investment cycle underway; assess returns on deployment.
Strong top-line growth of 296.4% — accelerating demand or successful expansion into new markets.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Net income declined 140.6% — review whether driven by operations, interest costs, or non-recurring items.
Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.
Cash declined 43% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Debt increased 42.2% — substantial leverage increase; assess whether deployed for growth or covering losses.
Inventory surged 36.9% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
Receivables declined — improved collection efficiency or conservative revenue recognition.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →